Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
April 11, 2024 08:05 ET | Enlivex Therapeutics Ltd
Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and efficacy topline analysis includes...
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
March 13, 2024 08:14 ET | Clearmind Medicine Inc.
Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery...
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
February 29, 2024 08:35 ET | SciSparc Ltd
The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in accordance with enrollment initiation TEL AVIV, Israel, Feb. 29,...
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
February 23, 2024 07:06 ET | Clearmind Medicine Inc.
For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine...
MNPR Triangle 2.JPG
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
February 20, 2024 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
February 12, 2024 16:05 ET | G1 Therapeutics
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
February 01, 2024 08:15 ET | Clearmind Medicine Inc.
The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving Tel Aviv, Israel / Vancouver,...
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
January 29, 2024 07:18 ET | SciSparc Ltd
The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market TEL AVIV,...
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 29, 2023 07:45 ET | SciSparc Ltd
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
September 07, 2023 09:15 ET | SciSparc Ltd
Initiation of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...